Abdullaev F I. 2002. Cancer chemopreventive and tumoricidal properties of saffron (Crocus sativus L.). Exp Biol Med, 227: 20–25.
Abe K, Saito H. 2000. Effects of saffron and its constituent crocin on learning behavior and long-term potentiation. Phytother Res, 14: 149-152.
Adongo DW, Kukuia KK, Mante PK, Ameyaw EO, Woode E. 2015. Antidepressant Like Effect of the Leaves of Pseudospondias microcarpa in Mice. BioMed Res Int, doi: 10.1155/397943.
Akhondzadeh S, Fallah Pour H, Afkham K, Jamshidi AH, Khalighi Cigarodi F. 2004. Comparison of Crocus sativus L. and imipramine in the treatment of mild to moderate depression. BMC Comp Alt Med, 4: 12.
Bottiglieri T. 2005. Homocysteine and folate metabolism in depression. Prog NeuroPsychophermacol Biol Psychiatry, 29: 1103–1112.
Bottiglieri T, Laundy M, Crellin R, Toone BK, Carney MWP, Reynolds EH, 2000. Monoamine metabolism in depression. Psychol Med J, 69: 228–232.
Budge MM, De Jager C, Hogervorst E, Smith AD, 2002. Memory TOPTI .Total plasma homocysteine, age, systolic blood pressure, and cognitive performance in older people. J Am Geriatr Soc, 50:2014-2018.
Bukharaeva E, Shakirzyanova A, Khuzakhmetova V, Sitdikova G, Giniatullin R. 2015. Homocysteine aggravates ROS-induced depression of transmitter release from motor nerve terminals . Frontiers Cell Neurosci, 9:391
Demyttenaere, K. 1997. Compliance during treatment with antidepressants. J Affect Disord, 43:27-39.
Fava M, Borus JS, Alpert JE, Nierenberg AA, Rosenbaum JF. 1997. Folate, vitamin B12, and homocysteine in major depressive disorder. Am J Psychiatry, 154:426-8.
Hosseinzadeh H, Sadeghnia HR, Rahimi A. 2008. Effect of safranal on extracellular hippocampal levels of glutamate and aspartate during kainic acid treatment in anesthetized rats. Planta Med b, 74:1441–1445.
Holford P. 2003. Invited papers Depression the nutrition connection. Primary Care Mental Health, 1: 9– 16.
Khazdair MR, Boskabady MH, Hosseini M, Rezaee R, Tsatsakis A. 2015. Avicenna J Phytomed, 5:376-391. Review.
Koz ST, Etem EO, Baydas G, Yuce H, Ozercan HI, Kuloğlu T, Koz S, Etem A, Demir N. 2012.
Effects of resveratrol on blood homocysteine level, on homocysteine induced oxidative stress, apoptosis and cognitive dysfunctions in rats.Brain Res, 1484:29-38.
Lentz SR . 1997. Homocysteine and vascular dysfunction. Life sci, 61: 1205–1215
Lechtenberg MD, Schepmann M, Niehues N, Hellenbrand B, ¨unsch W, Hensel A. 2008. Quality and functionality of saffron: quality control, species assortment and affinity of extract and isolated saffron compounds to NMDA and σ 1(Sigma-1) receptors. Planta Medica, 74:764–772.
MacDonald TM, Reid IC, McMahon AD. 1997. Patients receive an inadequate dose of antidepressants for an inadequate period BMJ, 315:56
Noorbala AA, Akhondzadeh S, Tamacebi-Pour N, Jamshidi AH, 2005. Hydro-alcoholic extract of Crocus sativus L. versus fluoxetine in the treatment of mild to moderate depression: a double-blind, randomized pilot trial , J Ethnopharmacol, 97:281-284.
Nolen Hoeksema S, Girgus JS. 1994. The emergence of gender differences in depression during adolescence. Psychol Bull, 115: 424–443
Plante GE . 2005. Depression and cardiovascular disease: a reciprocal relationship. Metabolism Review, 54:45-48..
Rinki K, Agrawal A, Singh G. 2015. Dubey Hyperhomocysteinemia as risk factor for depression: A review . Pharm Biol Evalu, 2: 133-141
Rios JL, Recio MC, Giner RM, Manez S. 1996. An update review of saffron and its active constituents. Phytother Res, 10: 189–193.
Schildkraut JJ. 1965. J Neuropsychiatry Clin Neurosci. 7:524-533.
Sachdev PS, Parslow RA, Lux O, Salonikas C, Wen W. 2005. Psychological medicine, 35: 529–538
Topić R, Aukst Margetić B, Ćima A, Štimac Z, Jakovljević M. 2010. P02-325 - Personality types A/B and D, cholesterol and homocystein in major depression compared to PTSD with and without depression European Psychiatry, 25: 1034
Tolmunen T, Hintikka J, Voutilainen S, Ruusunen A, Alfthan G. 2004. Association between depressive symptoms and serum concentrations of homocysteine in men: a population study. Am j clinical nutrition, 80: 1574–1578
Waldmeier PC, Spooren WP, Hengerer B. 2000. Protects CGP 3466 dopaminergic neurons in lesion models of Parkinson's disease. Naunyn Schmiedebergs Arch Pharmacol, 362:526-537.